Monopar Therapeutics Form 4 insider transactions

Christopher M Starr, a Director of Monopar Therapeutics, sold 8,400 shares of common stock on October 1, 2026.

Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, reported multiple transactions in common stock on September 30, 2026.

Chandler Robinson, Chief Executive Officer and a Director of Monopar Therapeutics, reported multiple transactions in common stock on September 30, 2026.

Quan Anh Vu, Chief Financial Officer of Monopar Therapeutics, reported multiple transactions in common stock on September 30, 2026.

Chandler Robinson, Chief Executive Officer and a Director of Monopar Therapeutics, sold 29,056 shares of common stock on September 24, 2026.

Kim R Tsuchimoto, a Director of Monopar Therapeutics, sold 4,090 shares of common stock on August 26, 2026.

Raymond Anderson, a Director of Monopar Therapeutics, sold 3,142 shares of common stock on August 25, 2026.

Patrice Rioux, Acting Chief Medical Officer of Monopar Therapeutics, sold 1 shares of common stock on August 26, 2026 for $111.26 per share.

Kim R Tsuchimoto, a Director of Monopar Therapeutics, sold 4,090 shares of common stock on August 26, 2026.

Raymond Anderson, a Director of Monopar Therapeutics, sold 3,142 shares of common stock on August 25, 2026.

Monopar Therapeutics Chief Financial Officer, Quan Anh Vu, has acquired shares through the vesting and settlement of restricted stock units, with a portion withheld for taxes.

Chandler Robinson, CEO and Director of Monopar Therapeutics, reported transactions involving restricted stock units and common stock.

Monopar Therapeutics reports that Chief Operating Officer Andrew Cittadine acquired shares through the vesting and settlement of restricted stock units.

Monopar Therapeutics Director Nicole Sweeny acquired 1,284 stock options with an exercise price of $87.68, vesting in two tranches.

CEO Chandler Robinson acquired 6,732 shares of Monopar Therapeutics common stock through the vesting of restricted stock units.

Monopar Therapeutics Chief Operating Officer Andrew Cittadine acquired 3,514 shares via RSU vesting and withheld 1,571 shares for taxes.

Monopar Therapeutics' Chief Commercial and Strategy Officer, Susan Rodriguez, was granted 48,728 stock options with an exercise price of $53.47, vesting over four years.

Monopar Therapeutics CEO Chandler Robinson reported the indirect acquisition of 62,815 common shares through a pro rata liquidating distribution from Tactic Pharma, LLC, resulting in a net decrease in his total beneficial ownership.

Monopar Therapeutics CEO Chandler Robinson reported the acquisition of 8,724 common shares through RSU vesting and the disposition of 2,558 shares for tax withholding.

Monopar Therapeutics' COO, Andrew Cittadine, reported an increase in direct common stock ownership following RSU vesting and tax-related share disposition.

Monopar Therapeutics reported an equity grant of 2,000 stock options to Patrice Rioux, its Acting Chief Medical Officer, with an exercise price of $65.3.

Monopar Therapeutics' Chief Financial Officer, Quan Anh Vu, reported a planned acquisition of 1,500 shares of common stock at $69.95 per share under a Rule 10b5-1 plan.

Monopar Therapeutics director Arthur J. Klausner reported the sale of 5,121 shares of common stock in pre-planned transactions.

Diane Hendricks, a Director and 10% owner of Monopar Therapeutics, reported an indirect disposition of 43,499 shares of common stock with no pecuniary interest.

Monopar Therapeutics Director Arthur J. Klausner reported acquiring 7,710 shares of common stock through a pro rata distribution.

Monopar Therapeutics' Chief Operating Officer, Andrew Cittadine, acquired stock options and restricted stock units on December 2, 2025, as part of an equity compensation plan.

Monopar Therapeutics director Christopher M. Starr was granted 2,924 stock options with an exercise price of $75.94, vesting quarterly through 2026.

Monopar Therapeutics director Arthur J. Klausner was granted 2,924 stock options with an exercise price of $75.94, vesting quarterly through 2026.

Monopar Therapeutics director Raymond Anderson was granted 2,924 stock options with an exercise price of $75.94, vesting quarterly through 2026.

Monopar Therapeutics director Lavina Talukdar received a grant of 2,924 stock options with an exercise price of $75.94, vesting quarterly through 2026.